List of Excipients in Branded Drug ALLEGRA ALLERGY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chattem Inc	ALLEGRA ALLERGY	fexofenadine hydrochloride	41167-4122	CELLULOSE, MICROCRYSTALLINE
Chattem Inc	ALLEGRA ALLERGY	fexofenadine hydrochloride	41167-4122	CROSCARMELLOSE SODIUM
Chattem Inc	ALLEGRA ALLERGY	fexofenadine hydrochloride	41167-4122	D&C RED NO. 28
Chattem Inc	ALLEGRA ALLERGY	fexofenadine hydrochloride	41167-4122	D&C RED NO. 33
Chattem Inc	ALLEGRA ALLERGY	fexofenadine hydrochloride	41167-4122	FD&C BLUE NO. 1
Chattem Inc	ALLEGRA ALLERGY	fexofenadine hydrochloride	41167-4122	GELATIN

Allegra Allergy Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Allegra Allergy is an over-the-counter fexofenadine hydrochloride product with limited remaining exclusivity value and substantial formulation flexibility. The commercial opportunity is concentrated in differentiated delivery systems, pediatric and geriatric usability, clean-label positioning, private-label supply, and geographic expansion rather than in protecting the active ingredient.

What is Allegra Allergy and which active ingredient does it contain?

Allegra Allergy is a U.S. OTC allergy product containing fexofenadine hydrochloride, a second-generation H1 antihistamine. The principal consumer product is the 24-hour, 180 mg tablet used for relief of seasonal allergic rhinitis symptoms and chronic idiopathic urticaria symptoms.[1]

Attribute	Allegra Allergy
Active ingredient	Fexofenadine hydrochloride
Common strength	180 mg
Drug class	Second-generation H1 antihistamine
U.S. status	OTC
Original prescription approval	FDA NDA 20-625, 1996
OTC switch	1999
Primary dosage forms	Tablets, orally disintegrating tablets, oral liquid products and capsules under the Allegra franchise
Reference brand company	Sanofi Consumer Healthcare; consumer-health operations were transferred into Opella in stages beginning in 2024
Biosimilar risk	None
Generic risk	High
Core commercial constraint	Fexofenadine is a mature, widely available generic active ingredient

FDA approved fexofenadine hydrochloride for prescription use in 1996 and approved the nonprescription switch in 1999. The active ingredient is the carboxylic-acid metabolite of terfenadine and does not have the same cardiac safety profile associated with terfenadine at recommended doses.[2]

What excipients are used in Allegra Allergy tablets?

The Allegra Allergy tablet platform uses conventional direct-compression and film-coating excipients. Product-specific inactive ingredients can vary by strength, market, dosage form and manufacturing site. U.S. labeling identifies excipient classes that include microcrystalline cellulose, starch-based disintegrants, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate and hypromellose-based coating materials.[3]

Functional role of the principal excipients

Excipient or class	Likely formulation role	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet robustness and scalable manufacturing
Corn starch or pregelatinized starch	Diluent and disintegrant	Enables cost-effective tablet processing
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup
Sodium starch glycolate	Superdisintegrant	Provides additional disintegration capacity where used
Povidone	Binder	Improves granule or tablet mechanical strength
Colloidal silicon dioxide	Glidant and moisture-flow aid	Supports powder flow and content uniformity
Magnesium stearate	Lubricant	Reduces tooling friction during compression
Hypromellose	Film former and coating polymer	Supports appearance, swallowability and product identification
Iron oxides or other colorants	Color system	Allows brand differentiation, but can limit clean-label positioning

The current excipient strategy is economically conservative. It uses widely available pharmaceutical-grade materials with established compendial and regulatory histories. That reduces manufacturing risk and supports large-scale contract manufacturing or private-label production.

What formulations are protected by Allegra Allergy?

No major formulation barrier prevents generic or private-label competitors from selling conventional fexofenadine tablets. The commercial value of Allegra's formulation portfolio lies in consumer recognition, regulatory history, packaging, flavor systems and product execution rather than in a durable composition-of-matter patent.

Relevant formulation categories include:

1. Immediate-release 24-hour tablets.
2. Pediatric oral liquids.
3. Orally disintegrating or fast-dissolving tablets.
4. Combination products containing fexofenadine with a decongestant such as pseudoephedrine.
5. Market-specific capsules or caplets.

The exact inactive-ingredient profile must be evaluated by National Drug Code, dosage form and market. A label for one Allegra product should not be used to infer the excipient composition of every Allegra product.

Immediate-release tablet strategy

The standard 180 mg tablet is the lowest-risk manufacturing platform. A generic competitor can generally reproduce the same release profile using common fillers, binders, disintegrants and lubricants. The key development controls are:

• Assay and content uniformity for a relatively high-dose active.
• Rapid disintegration without excessive friability.
• Dissolution performance across relevant pH conditions.
• Low moisture uptake.
• Tablet hardness sufficient for OTC packaging and shipping.
• Consistent coating color and visual identity.
• Compatibility with unit-dose blistering and bottles.

Fexofenadine hydrochloride is highly water-soluble relative to many poorly soluble antihistamines. The development challenge is therefore less about aggressive solubility enhancement and more about physical stability, powder flow, compression, dissolution consistency and palatability in liquid products.

Oral liquid strategy

Liquid products create more differentiation than standard tablets but carry higher development and quality risk. Key excipient decisions include:

• Buffer selection to control pH.
• Sweetener system, including sucrose, sorbitol, sucralose or other high-intensity sweeteners.
• Flavor masking for the active ingredient.
• Preservative system.
• Suspending or viscosity-modifying agents, if needed.
• Alcohol-free and sugar-free positioning.
• Compatibility with dosing syringes and child-resistant closures.

A pediatric liquid can address families that cannot use tablets and can support a higher retail price per active-ingredient dose. The principal barriers are taste, preservative validation, microbial control, sedimentation or phase separation, and accurate dosing across the shelf life.

Orally disintegrating tablet strategy

An orally disintegrating tablet can target children, older adults and consumers who have difficulty swallowing conventional tablets. The excipient platform typically requires:

• A highly porous or low-density tablet matrix.
• Rapid-wetting agents.
• Specialized superdisintegrants.
• Taste masking.
• Low-force compression to prevent delayed disintegration.
• Moisture-protective packaging.

This format can command a premium, but it is vulnerable to copycat competition if the formulation does not provide a meaningful sensory or performance advantage. A true ODT must meet applicable FDA performance expectations for rapid disintegration and labeling.[4]

When does Allegra Allergy lose exclusivity?

Fexofenadine's core pharmaceutical exclusivity has expired. FDA approved generic fexofenadine hydrochloride products long ago, and multiple manufacturers compete in the U.S. OTC and prescription markets.

Exclusivity category	Status
Composition-of-matter exclusivity	Expired
Original prescription exclusivity	Expired
OTC switch exclusivity	Expired
Conventional tablet generic entry	Permitted
Biosimilar exclusivity	Not applicable
Brand-only protection	Primarily trademark, trade dress, marketing and distribution
Formulation protection	Potentially relevant only for specific improved products, not the basic active ingredient

The principal legal assets now are trademarks, packaging, trade dress, product-specific know-how, supplier arrangements and regulatory files. A new patent could protect a genuinely novel formulation or manufacturing process, but it would not prevent competitors from selling ordinary fexofenadine tablets.

What is the Orange Book status of Allegra Allergy?

FDA's Orange Book framework is relevant to the underlying approved prescription NDA and abbreviated applications, but the retail Allegra Allergy product is sold OTC. The Orange Book does not create ongoing market exclusivity for the Allegra brand.

The practical regulatory position is:

• The underlying fexofenadine NDA established the reference product.
• Generic fexofenadine products can rely on the applicable FDA abbreviated approval pathway.
• OTC competitors can also commercialize products under an approved NDA, an applicable OTC monograph where permitted, or another FDA-recognized regulatory pathway.
• The Allegra trademark remains commercially important even though the active ingredient is generic.

FDA Drugs@FDA and the Orange Book should be checked by product identifier when conducting an acquisition, launch or litigation review because the applicable patent and exclusivity entries can differ by NDA and dosage form.[5]

Which companies are challenging Allegra Allergy?

Competition comes from three groups:

Generic pharmaceutical manufacturers

Generic fexofenadine is available from manufacturers including large U.S. generic companies, specialty suppliers and private-label manufacturers. Retailers can source equivalent products at lower prices, especially for 30-count and 90-count tablet packages.

Retailer private labels

CVS, Walgreens, Walmart, Target, Amazon and grocery retailers can sell store-brand fexofenadine products manufactured by third-party suppliers. Private-label products compete primarily on price, package count and retailer placement.

Other branded antihistamines

Allegra competes with cetirizine, levocetirizine, loratadine and desloratadine products, including Zyrtec, Xyzal and Claritin. These products are not direct excipient substitutes in every respect, but consumers often switch among them based on perceived onset, sedation, duration, price and physician recommendation.

What generic entry risks exist for Allegra Allergy?

Generic entry risk is high because the active ingredient is mature, the standard tablet is technically straightforward and several substitute antihistamines are available.

Generic launch scenarios

Scenario	Commercial effect on Allegra
Low-price store brand expansion	Erodes unit volume and forces promotions
Large generic manufacturer entry	Increases pharmacy substitution and wholesale pressure
Premium ODT or liquid launch	Diverts pediatric and swallowing-impaired users
Combination-product launch	Captures consumers seeking allergy and congestion relief
Online private-label expansion	Reduces brand visibility and compresses price
Retailer-exclusive packaging	Weakens brand differentiation at the shelf

A branded product can retain share through reliable supply, advertising, packaging, seasonal promotions and product formats that are harder to match. The conventional 180 mg tablet alone provides limited protection against price competition.

Are there Paragraph IV challenges or fexofenadine patent lawsuits?

Fexofenadine's principal generic-entry disputes occurred during the historical prescription-to-generic transition. The current commercial issue is not a live, brand-blocking Paragraph IV dispute over the basic fexofenadine molecule.

A Paragraph IV certification is relevant when a generic applicant challenges a listed patent for an approved reference product. For mature fexofenadine tablets, the relevant patent terms have expired or no longer provide an effective barrier to routine generic launch. Product-specific litigation could still arise over a newly patented formulation, delivery system, trade dress or manufacturing process, but that would be narrower than a challenge to Allegra's active ingredient.

No biosimilar litigation applies because fexofenadine is a small molecule, not a biologic.

How strong is the Allegra patent estate?

The patent estate is weak for the base product and potentially stronger for new delivery systems.

Asset type	Estimated strategic strength
Fexofenadine active ingredient	Low; expired core protection
Conventional 180 mg tablet	Low
Basic excipient combination	Low unless technically unexpected
Taste-masked pediatric liquid	Moderate if supported by novel data
ODT technology	Moderate, depending on claims and freedom to operate
Combination with a decongestant	Low to moderate; heavily exposed to prior art
Manufacturing process	Moderate if the process reduces impurities or improves yield
Packaging and dosing system	Moderate commercially, limited as a pharmaceutical patent barrier
Trademark and trade dress	Stronger than the active-ingredient patent position

A credible new patent position would require more than selecting common excipients. Claims would need to cover a specific composition, manufacturing process, particle-size distribution, dissolution profile, stability improvement, taste-masking system or delivery device supported by comparative data.

What excipient opportunities exist for new Allegra products?

Dye-free and clean-label tablets

A dye-free product can target consumers who avoid colorants and reduce formulation complexity. The trade-off is weaker visual differentiation and a greater need for packaging controls to prevent mix-ups.

Sugar-free pediatric liquid

A sugar-free formulation could support dental-health positioning and broader use among children with dietary restrictions. Polyol systems can introduce gastrointestinal tolerability issues, while high-intensity sweeteners may require more extensive taste work.

Alcohol-free liquid

An alcohol-free formulation is commercially attractive for pediatric and family use. It also simplifies consumer messaging, although it places more pressure on preservative efficacy and microbial-control studies.

Fast-dissolve products

A rapid-disintegration tablet can capture consumers who dislike swallowing tablets. The main development risk is taste. Fexofenadine's sensory profile must be managed through flavor, sweetener, coating or particulate taste-masking technology.

Unit-dose and travel packaging

Blister strips, stick packs and individually sealed liquid doses can increase convenience and reduce dosing errors. These options also support premium pricing and seasonal merchandising.

Combination products

Fexofenadine-pseudoephedrine products address congestion as well as allergy symptoms. They may produce higher revenue per package but face added regulatory, labeling and safety complexity. Pseudoephedrine controls, state restrictions and consumer suitability narrow the addressable market.

Vegan and allergen-positioned products

Replacing animal-derived processing aids or uncertain excipient sources can support vegan, vegetarian, gluten-free or allergen-conscious claims. These claims require supply-chain verification and disciplined labeling review.

How does Allegra compare with Claritin, Zyrtec and Xyzal?

Brand	Active ingredient	Main commercial positioning	Excipient opportunity
Allegra	Fexofenadine	Non-drowsy, 24-hour allergy relief	ODT, liquid, dye-free and family formats
Claritin	Loratadine	Once-daily, non-drowsy allergy relief	Chewables, dissolving products and liquid
Zyrtec	Cetirizine	Strong symptom relief and rapid consumer recognition	Chewables, liquids and combination products
Xyzal	Levocetirizine	Allergy relief with premium positioning	Smaller premium formats and pediatric delivery

Consumer switching limits the ability of any brand to rely solely on active-ingredient differentiation. Excipient execution matters most where it changes usability: taste, swallowability, disintegration, dosing accuracy, storage or dietary compatibility.

What licensing and manufacturing opportunities exist?

The most practical licensing targets are formulation and platform technologies rather than fexofenadine itself.

Potential deal structures include:

• Licensing an ODT platform for fexofenadine.
• Acquiring a pediatric taste-masking system.
• Contract development and manufacturing of liquid products.
• Private-label supply for retailers.
• Regional trademark licensing for Allegra-branded products.
• Co-development of unit-dose packaging.
• Licensing an alcohol-free preservative system.
• Supply agreements for high-purity fexofenadine hydrochloride.
• Geographic rights for markets where Allegra has lower penetration.

Manufacturing barriers are modest for tablets but higher for liquids and ODTs. Relevant diligence areas include active-ingredient supply qualification, impurity profiles, compression tooling, coating capacity, preservative efficacy, packaging moisture protection, child-resistant closures and seasonal capacity planning.

What geographic coverage does Allegra have?

Allegra is a global consumer-health brand, but the brand name, approved indication, dosage strength and regulatory pathway vary by country. Fexofenadine is marketed internationally under Allegra and other local brand names.

Geographic expansion opportunities are strongest where:

• Seasonal allergic rhinitis is underpenetrated.
• OTC antihistamine access is expanding.
• Consumers are shifting from sedating first-generation antihistamines.
• Pediatric liquid and ODT formats are underdeveloped.
• Local manufacturers seek premium branded or licensed products.

A global excipient strategy must account for local permitted colors, sweeteners, preservatives, allergen statements, pharmacopeial requirements, language-specific labeling and different OTC classification rules.

What is the commercial value of the Allegra excipient strategy?

The base tablet excipient system has low standalone strategic value because competitors can reproduce it with standard materials. The higher-value opportunities are:

1. Extending the franchise into differentiated formats.
2. Improving consumer adherence through palatability and ease of use.
3. Supporting premium price points with pediatric, geriatric or travel products.
4. Reducing manufacturing cost through robust direct compression.
5. Creating retailer-specific packages and private-label supply.
6. Protecting new products through formulation patents and regulatory exclusivity where available.
7. Building claims around dye-free, sugar-free, alcohol-free or vegan composition.

Public company reporting generally does not isolate Allegra revenue from broader consumer-health portfolios. Revenue exposure should therefore be modeled using SKU-level sales, retailer data, seasonality, gross-to-net deductions and generic price erosion rather than relying on corporate segment disclosure.

Key Takeaways

• Allegra Allergy contains fexofenadine hydrochloride and is a mature OTC antihistamine franchise.
• Core active-ingredient and conventional-tablet exclusivity has expired.
• The standard excipient platform uses common fillers, binders, disintegrants, glidants, lubricants and coating polymers.
• Generic and private-label competition is structurally high.
• No biosimilar risk exists because fexofenadine is a small molecule.
• The strongest commercial opportunities are pediatric liquids, ODTs, dye-free tablets, alcohol-free products, unit-dose packaging and carefully managed combination products.
• New patent value would depend on a technically specific formulation or manufacturing improvement, not on a routine excipient substitution.
• The Allegra trademark, consumer awareness, retail execution and supply reliability are more important than legacy patent protection.

FAQs

Can a company launch a private-label fexofenadine product using similar excipients?

Yes. A private-label manufacturer can develop an equivalent fexofenadine product using common pharmaceutical excipients, subject to applicable FDA approval, OTC requirements, labeling and manufacturing controls.

Does Allegra have a formulation patent that blocks generic tablets?

The expired protection around fexofenadine does not block ordinary generic tablets. A separate patent could affect a particular new dosage form, but it would not automatically prevent all fexofenadine products.

Which excipient is most important for an Allegra ODT?

Taste-masking technology is usually more commercially important than any single disintegrant. The product must combine rapid wetting and disintegration with acceptable mouthfeel and flavor.

Is fexofenadine suitable for a sugar-free pediatric formulation?

Yes, but the formulation requires careful selection of sweeteners, flavors, viscosity modifiers and preservatives. Polyol load and gastrointestinal tolerability require specific assessment.

Can Allegra be reformulated as a prescription-to-OTC lifecycle product again?

A new dosage form or indication could support a separate regulatory and commercial strategy, but the mature active ingredient would not by itself create meaningful new exclusivity. The value would need to come from formulation differentiation, clinical positioning, packaging or a new indication.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Allegra Allergy fexofenadine hydrochloride tablet, film coated. National Library of Medicine.
2. U.S. Food and Drug Administration. (1996). Approval package for Allegra (fexofenadine hydrochloride), NDA 20-625.
3. National Library of Medicine. (n.d.). DailyMed drug label information for fexofenadine hydrochloride products.
4. U.S. Food and Drug Administration. (2008). Guidance for industry: Orally disintegrating tablets.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.